加载中
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.
收盘时
US$2.56
+US$0.1713 · +7.17%
盘后
US$2.56
US$0.00 · 0.00%
10月13日 16:10 ET
盘中时间采用ET。市场数据可能有所延迟。
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.
日内区间
当前US$2.56
52周区间
当前US$2.56
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
47
合理估值
情绪
55
多空交织
风险
74
高风险
动量
17
强势下行
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.
日内区间
当前US$2.56
52周区间
当前US$2.56
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | — | 1.7万 USD | 2.3万 USD | 8000 USD | 2.3万 USD |
| 毛利 | — | −1.7万 USD | −2.3万 USD | −8000 USD | −2.3万 USD |
| 研究与开发 | 2118.5万 USD | 1411.7万 USD | 1733.4万 USD | 1508.3万 USD | 921万 USD |
| 销售、一般及管理费用 | 1595.6万 USD | 1350.4万 USD | 1404.3万 USD | 1260.8万 USD | 1131.1万 USD |
| 营业费用 | 3714.1万 USD | 2762.1万 USD | 3137.7万 USD | 2769.1万 USD | 2052.1万 USD |
| 利息收入 | 237.7万 USD | 405万 USD | 434.3万 USD | 87.7万 USD | 6000 USD |
| 折旧和摊销 | 1.6万 USD | 1.7万 USD | 2.3万 USD | 8000 USD | 2.3万 USD |
| 营业利润 | −3714.1万 USD | −2762.1万 USD | −3137.7万 USD | −2769.1万 USD | −2052.1万 USD |
| 净利润 | −3477万 USD | −2550.4万 USD | −3009.4万 USD | −2696万 USD | −2060.6万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2026年2月2日 | 1:15 | — | — |
股票拆分 | 2018年4月20日 | 1:12 | — | — |
股票拆分 | 2016年8月26日 | 1:15 | — | — |
已生效 2026年2月2日
1:15
已生效 2018年4月20日
1:12
已生效 2016年8月26日
1:15
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
